Investment Analysts’ Recent Ratings Updates for AdaptHealth (AHCO)

A number of firms have modified their ratings and price targets on shares of AdaptHealth (NASDAQ: AHCO) recently:

• 8/8/2026 – AdaptHealth was downgraded by Wall Street Zen from “buy” to “hold”.
• 8/6/2026 – AdaptHealth had its price target lowered by UBS Group AG from $14.00 to $10.00. They now have a “buy” rating on the stock.
• 8/6/2026 – AdaptHealth had its price target lowered by Royal Bank Of Canada from $15.00 to $8.00. They now have an “outperform” rating on the stock.
• 8/5/2026 – AdaptHealth had its price target lowered by Truist Financial Corporation from $14.00 to $9.00. They now have a “buy” rating on the stock.
• 8/5/2026 – AdaptHealth was given a new $10.00 price target by Robert W. Baird.
• 8/5/2026 – AdaptHealth was given a new $10.00 price target by Canaccord Genuity Group Inc..
• 7/21/2026 – AdaptHealth was upgraded by Jefferies Financial Group Inc. from “hold” to “buy”. They now have a $13.00 price target on the stock, up from $11.00.
• 7/6/2026 – AdaptHealth had its price target lowered by Robert W. Baird from $18.00 to $15.00. They now have an “outperform” rating on the stock.
• 6/14/2026 – AdaptHealth was upgraded by Wall Street Zen from “hold” to “buy”.

Insiders Place Their Bets

In related news, Director Kenneth A. Samet purchased 23,500 shares of the stock in a transaction dated Thursday, August 6th. The stock was bought at an average cost of $6.38 per share, for a total transaction of $149,930.00. Following the completion of the acquisition, the director owned 48,569 shares of the company’s stock, valued at approximately $309,870.22. This represents a 93.74% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Russell E. Schuster III sold 11,275 shares of the stock in a transaction on Monday, June 1st. The shares were sold at an average price of $10.06, for a total value of $113,426.50. Following the completion of the transaction, the insider owned 136,538 shares of the company’s stock, valued at $1,373,572.28. The trade was a 7.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 1.95% of the company’s stock.

AdaptHealth, Inc operates as a leading provider of home medical equipment (HME) and related services in the United States. The company focuses on delivering respiratory care, mobility solutions and bathroom safety products to patients with chronic and acute medical needs. Through its comprehensive service offerings, AdaptHealth aims to enhance quality of life and clinical outcomes for patients who require long-term support outside of a hospital setting.

The company’s respiratory portfolio includes products such as continuous positive airway pressure (CPAP) devices, oxygen concentrators, ventilators, and associated supplies for patients with sleep apnea, COPD and other pulmonary conditions.